Literature DB >> 22000672

The sFlt-1/PlGF ratio in different types of hypertensive pregnancy disorders and its prognostic potential in preeclamptic patients.

Stefan Verlohren1, Ignacio Herraiz, Olav Lapaire, Dietmar Schlembach, Manfred Moertl, Harald Zeisler, Pavel Calda, Wolfgang Holzgreve, Alberto Galindo, Theresa Engels, Barbara Denk, Holger Stepan.   

Abstract

OBJECTIVE: The soluble fms-like tyrosine kinase (sFlt-1)/placental growth factor (PlGF) ratio is a reliable tool in the assessment of preeclampsia. We tested the hypothesis that the sFlt-1/PlGF ratio is able to identify women at risk for imminent delivery. We characterized the sFlt-1/PlGF ratio in different types of hypertensive pregnancy disorders. STUDY
DESIGN: We investigated 388 singleton pregnancies with normal pregnancy outcome, 164 with PE, 36 with gestational hypertension, and 42 with chronic hypertension. sFlt-1 and PlGF were measured in serum samples.
RESULTS: Patients with preeclampsia had a significantly increased sFlt-1/PlGF ratio as compared with controls and with patients with chronic and gestational hypertension in <34 weeks and ≥34 weeks (P < .001). Time to delivery was significantly reduced in women with preeclampsia in the highest quartile of the sFlt-1/PlGF ratio (P < .001).
CONCLUSION: The sFlt-1/PlGF ratio allows the identification of women at risk for imminent delivery and is a reliable tool to discriminate between different types of pregnancy-related hypertensive disorders.
Copyright © 2012 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22000672     DOI: 10.1016/j.ajog.2011.07.037

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  79 in total

Review 1.  Molecular Mechanisms of Preeclampsia.

Authors:  Tammy Hod; Ana Sofia Cerdeira; S Ananth Karumanchi
Journal:  Cold Spring Harb Perspect Med       Date:  2015-08-20       Impact factor: 6.915

2.  Preeclampsia - Aetiology, Current Diagnostics and Clinical Management, New Therapy Options and Future Perspectives.

Authors:  A-C Tallarek; B Huppertz; H Stepan
Journal:  Geburtshilfe Frauenheilkd       Date:  2012-12       Impact factor: 2.915

3.  Increased circulating levels of Epidermal Growth Factor-like Domain 7 in pregnant women affected by preeclampsia.

Authors:  Micol Massimiani; Lauretta A Lacko; Clare S Burke Swanson; Silvia Salvi; Lissenya B Argueta; Sascia Moresi; Sergio Ferrazzani; Shari E Gelber; Rebecca N Baergen; Nicola Toschi; Luisa Campagnolo; Heidi Stuhlmann
Journal:  Transl Res       Date:  2018-12-25       Impact factor: 7.012

Review 4.  Maternal Circulating microRNAs and Pre-Eclampsia: Challenges for Diagnostic Potential.

Authors:  Malia S Q Murphy; Chandrakant Tayade; Graeme N Smith
Journal:  Mol Diagn Ther       Date:  2017-02       Impact factor: 4.074

Review 5.  The Role of Cardiac Biomarkers in Pregnancy.

Authors:  Emily S Lau; Amy Sarma
Journal:  Curr Treat Options Cardiovasc Med       Date:  2017-07

6.  New Insights into the Pathogenesis of Preeclampsia - The Role of Nrf2 Activators and their Potential Therapeutic Impact.

Authors:  N Kweider; C J Wruck; W Rath
Journal:  Geburtshilfe Frauenheilkd       Date:  2013-12       Impact factor: 2.915

7.  Prenatal Clinical Assessment of sFlt-1 (Soluble fms-like Tyrosine Kinase-1)/PlGF (Placental Growth Factor) Ratio as a Diagnostic Tool for Preeclampsia, Pregnancy-induced Hypertension, and Proteinuria.

Authors:  H Lehnen; N Mosblech; T Reineke; A Puchooa; I Menke-Möllers; U Zechner; U Gembruch
Journal:  Geburtshilfe Frauenheilkd       Date:  2013-05       Impact factor: 2.915

8.  Diagnosis and Treatment of Hypertensive Pregnancy Disorders. Guideline of DGGG (S1-Level, AWMF Registry No. 015/018, December 2013).

Authors:  H Stepan; S Kuse-Föhl; W Klockenbusch; W Rath; B Schauf; T Walther; D Schlembach
Journal:  Geburtshilfe Frauenheilkd       Date:  2015-09       Impact factor: 2.915

9.  Phthalate metabolites and bisphenol-A in association with circulating angiogenic biomarkers across pregnancy.

Authors:  K K Ferguson; T F McElrath; D E Cantonwine; B Mukherjee; J D Meeker
Journal:  Placenta       Date:  2015-04-14       Impact factor: 3.481

10.  The course of angiogenic factors in early- vs. late-onset preeclampsia and HELLP syndrome.

Authors:  Wiebke Schaarschmidt; Sarosh Rana; Holger Stepan
Journal:  J Perinat Med       Date:  2013-09-01       Impact factor: 1.901

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.